BioMarin Pharmaceutical Inc. (0HNC.L)
USD 58.91
(-5.27%)
USD 58.91
(-5.27%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 1.1 Billion USD | 23.83% |
| 2022 | 894.08 Million USD | 15.12% |
| 2021 | 776.66 Million USD | 11.18% |
| 2020 | 698.54 Million USD | 2.69% |
| 2019 | 680.27 Million USD | 28.14% |
| 2018 | 530.87 Million USD | 11.58% |
| 2017 | 475.77 Million USD | 33.97% |
| 2016 | 355.12 Million USD | 30.71% |
| 2015 | 271.68 Million USD | 36.21% |
| 2014 | 199.45 Million USD | 22.66% |
| 2013 | 162.6 Million USD | 26.35% |
| 2012 | 128.69 Million USD | -1.09% |
| 2011 | 130.11 Million USD | 18.61% |
| 2010 | 109.69 Million USD | 39.45% |
| 2009 | 78.66 Million USD | 7.52% |
| 2008 | 73.16 Million USD | 125.5% |
| 2007 | 32.44 Million USD | 29.39% |
| 2006 | 25.07 Million USD | 130.09% |
| 2005 | 10.89 Million USD | 370.55% |
| 2004 | 2.31 Million USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | -100.0% |
| 2000 | 436 Thousand USD | -35.5% |
| 1999 | 676 Thousand USD | 576.0% |
| 1998 | 100 Thousand USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 1.13 Billion USD | 2.78% |
| 2024 Q2 | 1.18 Billion USD | 4.01% |
| 2024 Q3 | 1179.33 Billion USD | -0.36% |
| 2023 Q3 | 1.03 Billion USD | 5.8% |
| 2023 FY | 1.1 Billion USD | 23.83% |
| 2023 Q4 | 1.1 Billion USD | 7.27% |
| 2023 Q1 | 918.92 Million USD | 2.78% |
| 2023 Q2 | 975.54 Million USD | 6.16% |
| 2022 Q4 | 894.08 Million USD | 6.51% |
| 2022 Q3 | 839.46 Million USD | 4.63% |
| 2022 FY | 894.08 Million USD | 15.12% |
| 2022 Q1 | 786.35 Million USD | 1.25% |
| 2022 Q2 | 802.31 Million USD | 2.03% |
| 2021 Q3 | 749.4 Million USD | 5.41% |
| 2021 Q4 | 776.66 Million USD | 3.64% |
| 2021 FY | 776.66 Million USD | 11.18% |
| 2021 Q1 | 713.92 Million USD | 2.2% |
| 2021 Q2 | 710.97 Million USD | -0.41% |
| 2020 FY | 698.54 Million USD | 2.69% |
| 2020 Q3 | 700.84 Million USD | -5.78% |
| 2020 Q1 | 705.65 Million USD | 3.73% |
| 2020 Q2 | 743.85 Million USD | 5.41% |
| 2020 Q4 | 698.54 Million USD | -0.33% |
| 2019 Q3 | 609.04 Million USD | 5.24% |
| 2019 FY | 680.27 Million USD | 28.14% |
| 2019 Q1 | 534.69 Million USD | 0.72% |
| 2019 Q2 | 578.73 Million USD | 8.24% |
| 2019 Q4 | 680.27 Million USD | 11.69% |
| 2018 Q1 | 468.16 Million USD | -1.6% |
| 2018 FY | 530.87 Million USD | 11.58% |
| 2018 Q4 | 530.87 Million USD | 4.4% |
| 2018 Q3 | 508.48 Million USD | 7.42% |
| 2018 Q2 | 473.35 Million USD | 1.11% |
| 2017 Q3 | 457.39 Million USD | 6.41% |
| 2017 Q1 | 384.14 Million USD | 8.17% |
| 2017 FY | 475.77 Million USD | 33.97% |
| 2017 Q2 | 429.83 Million USD | 11.89% |
| 2017 Q4 | 475.77 Million USD | 4.02% |
| 2016 Q1 | 296.97 Million USD | 9.31% |
| 2016 Q4 | 355.12 Million USD | 2.22% |
| 2016 FY | 355.12 Million USD | 30.71% |
| 2016 Q3 | 347.42 Million USD | 6.39% |
| 2016 Q2 | 326.55 Million USD | 9.96% |
| 2015 Q1 | 222.83 Million USD | 11.72% |
| 2015 Q2 | 237.53 Million USD | 6.6% |
| 2015 Q4 | 271.68 Million USD | 3.66% |
| 2015 FY | 271.68 Million USD | 36.21% |
| 2015 Q3 | 262.1 Million USD | 10.34% |
| 2014 Q2 | 193.49 Million USD | 9.39% |
| 2014 FY | 199.45 Million USD | 22.66% |
| 2014 Q3 | 204.44 Million USD | 5.66% |
| 2014 Q4 | 199.45 Million USD | -2.44% |
| 2014 Q1 | 176.89 Million USD | 8.79% |
| 2013 Q3 | 148.68 Million USD | 4.49% |
| 2013 Q1 | 135.82 Million USD | 5.54% |
| 2013 Q2 | 142.29 Million USD | 4.77% |
| 2013 FY | 162.6 Million USD | 26.35% |
| 2013 Q4 | 162.6 Million USD | 9.36% |
| 2012 FY | 128.69 Million USD | -1.09% |
| 2012 Q4 | 128.69 Million USD | 6.51% |
| 2012 Q1 | 124.06 Million USD | -4.65% |
| 2012 Q2 | 120.12 Million USD | -3.17% |
| 2012 Q3 | 120.82 Million USD | 0.58% |
| 2011 Q4 | 130.11 Million USD | 12.53% |
| 2011 FY | 130.11 Million USD | 18.61% |
| 2011 Q3 | 115.62 Million USD | 2.96% |
| 2011 Q1 | 110.06 Million USD | 0.34% |
| 2011 Q2 | 112.29 Million USD | 2.03% |
| 2010 Q3 | 91.74 Million USD | 9.5% |
| 2010 FY | 109.69 Million USD | 39.45% |
| 2010 Q2 | 83.77 Million USD | 5.04% |
| 2010 Q1 | 79.76 Million USD | 1.4% |
| 2010 Q4 | 109.69 Million USD | 19.57% |
| 2009 Q4 | 78.66 Million USD | 4.27% |
| 2009 FY | 78.66 Million USD | 7.52% |
| 2009 Q1 | 76.42 Million USD | 4.46% |
| 2009 Q2 | 72.83 Million USD | -4.69% |
| 2009 Q3 | 75.44 Million USD | 3.58% |
| 2008 Q4 | 73.16 Million USD | 7.44% |
| 2008 Q3 | 68.09 Million USD | 10.18% |
| 2008 Q1 | 54.73 Million USD | 68.7% |
| 2008 Q2 | 61.8 Million USD | 12.91% |
| 2008 FY | 73.16 Million USD | 125.5% |
| 2007 FY | 32.44 Million USD | 29.39% |
| 2007 Q1 | 27.43 Million USD | 9.42% |
| 2007 Q2 | 30.71 Million USD | 11.94% |
| 2007 Q3 | 31.55 Million USD | 2.73% |
| 2007 Q4 | 32.44 Million USD | 2.83% |
| 2006 Q2 | 24.24 Million USD | 33.69% |
| 2006 Q3 | 25.76 Million USD | 6.25% |
| 2006 Q1 | 18.13 Million USD | 66.43% |
| 2006 FY | 25.07 Million USD | 130.09% |
| 2006 Q4 | 25.07 Million USD | -2.67% |
| 2005 FY | 10.89 Million USD | 370.55% |
| 2005 Q3 | 7.72 Million USD | 128.0% |
| 2005 Q2 | 3.38 Million USD | 38.83% |
| 2005 Q1 | 2.43 Million USD | 5.31% |
| 2005 Q4 | 10.89 Million USD | 41.17% |
| 2004 FY | 2.31 Million USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q2 | 2.07 Million USD | 0.0% |
| 2004 Q3 | 3.09 Million USD | 48.99% |
| 2004 Q4 | 2.31 Million USD | -25.05% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2001 Q4 | - USD | -100.0% |
| 2001 Q2 | 480 Thousand USD | 9.34% |
| 2001 Q1 | 439 Thousand USD | 0.69% |
| 2001 Q3 | 525 Thousand USD | 9.38% |
| 2001 FY | - USD | -100.0% |
| 2000 Q2 | 495 Thousand USD | -23.49% |
| 2000 Q3 | 446 Thousand USD | -9.9% |
| 2000 FY | 436 Thousand USD | -35.5% |
| 2000 Q1 | 647 Thousand USD | -4.29% |
| 2000 Q4 | 436 Thousand USD | -2.24% |
| 1999 Q3 | 900 Thousand USD | 12.5% |
| 1999 Q2 | 800 Thousand USD | 700.0% |
| 1999 Q1 | 100 Thousand USD | 0.0% |
| 1999 FY | 676 Thousand USD | 576.0% |
| 1999 Q4 | 676 Thousand USD | -24.89% |
| 1998 FY | 100 Thousand USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| uniQure N.V. | 12.02 Million USD | -9108.109% |
| Agios Pharmaceuticals, Inc. | 19.07 Million USD | -5704.063% |
| Amicus Therapeutics, Inc. | 59.69 Million USD | -1754.702% |
| Atara Biotherapeutics, Inc. | 9.7 Million USD | -11307.202% |
| bluebird bio, Inc. | 22.91 Million USD | -4730.852% |
| Cara Therapeutics, Inc. | 2.82 Million USD | -39147.891% |
| Imunon, Inc. | - USD | -Infinity% |
| Editas Medicine, Inc. | - USD | -Infinity% |
| IQVIA Holdings Inc. | - USD | -Infinity% |
| Mettler-Toledo International Inc. | 385.86 Million USD | -186.935% |
| Myriad Genetics, Inc. | 20.1 Million USD | -5408.373% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | -2790.817% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | -1330.321% |
| Verastem, Inc. | - USD | -Infinity% |
| Walgreens Boots Alliance, Inc. | 8.32 Billion USD | 86.693% |
| Waters Corporation | 516.23 Million USD | -114.472% |
| Thermo Fisher Scientific Inc. | 5.08 Billion USD | 78.239% |
| Biogen Inc. | 2.52 Billion USD | 56.193% |
| Nektar Therapeutics | 16.1 Million USD | -6776.486% |
| Perrigo Company plc | 1.14 Billion USD | 2.955% |
| Dynavax Technologies Corporation | 53.29 Million USD | -1977.656% |
| Illumina, Inc. | 587 Million USD | -88.617% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Iovance Biotherapeutics, Inc. | 10.37 Million USD | -10574.73% |
| Heron Therapeutics, Inc. | 42.11 Million USD | -2529.264% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| Sangamo Therapeutics, Inc. | - USD | -Infinity% |
| Evolus, Inc. | 10.99 Million USD | -9967.13% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Aclaris Therapeutics, Inc. | - USD | -Infinity% |
| Regeneron Pharmaceuticals, Inc. | 2.58 Billion USD | 57.094% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | -1587.187% |
| FibroGen, Inc. | 41.56 Million USD | -2563.739% |
| Agilent Technologies, Inc. | 1.03 Billion USD | -7.389% |
| OPKO Health, Inc. | 65.69 Million USD | -1585.287% |
| Homology Medicines, Inc. | - USD | -Infinity% |
| Geron Corporation | - USD | -Infinity% |
| Alnylam Pharmaceuticals, Inc. | 89.14 Million USD | -1141.988% |
| Exelixis, Inc. | 17.32 Million USD | -6291.404% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | - USD | -Infinity% |
| Zoetis Inc. | 2.56 Billion USD | 56.818% |
| Axsome Therapeutics, Inc. | 15.13 Million USD | -7215.382% |
| Abeona Therapeutics Inc. | -2.44 Million USD | 45402.087% |
| Vertex Pharmaceuticals Incorporated | 738.8 Million USD | -49.862% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 28.42 Million USD | -3795.103% |
| Sarepta Therapeutics, Inc. | 322.85 Million USD | -242.931% |
| Corcept Therapeutics Incorporated | 7.73 Million USD | -14223.195% |
| Halozyme Therapeutics, Inc. | 127.6 Million USD | -767.691% |
| Blueprint Medicines Corporation | 21.22 Million USD | -5116.901% |
| Insmed Incorporated | 83.24 Million USD | -1229.982% |
| TG Therapeutics, Inc. | 39.82 Million USD | -2680.26% |
| Incyte Corporation | 62.97 Million USD | -1658.215% |
| Emergent BioSolutions Inc. | 328.9 Million USD | -236.632% |